282 related articles for article (PubMed ID: 34551585)
1. Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy.
Hafez DA; Hassanin IA; Teleb M; Khattab SN; Elkhodairy KA; Elzoghby AO
Nanomedicine (Lond); 2021 Oct; 16(25):2305-2325. PubMed ID: 34551585
[TBL] [Abstract][Full Text] [Related]
2. β-Cyclodextrin-poly (β-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors.
Chaudhuri S; Fowler MJ; Baker C; Stopka SA; Regan MS; Sablatura L; Broughton CW; Knight BE; Stabenfeldt SE; Agar NYR; Sirianni RW
ACS Appl Mater Interfaces; 2021 May; 13(18):20960-20973. PubMed ID: 33905245
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics in cancer therapy and nanomedicine.
Roberti A; Valdes AF; Torrecillas R; Fraga MF; Fernandez AF
Clin Epigenetics; 2019 May; 11(1):81. PubMed ID: 31097014
[TBL] [Abstract][Full Text] [Related]
4. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
5. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
7. HDACiDB: a database for histone deacetylase inhibitors.
Murugan K; Sangeetha S; Ranjitha S; Vimala A; Al-Sohaibani S; Rameshkumar G
Drug Des Devel Ther; 2015; 9():2257-64. PubMed ID: 25945037
[TBL] [Abstract][Full Text] [Related]
8. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
Schobert R; Biersack B
Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
[TBL] [Abstract][Full Text] [Related]
9. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors in cancer therapy.
Lee MJ; Kim YS; Kummar S; Giaccone G; Trepel JB
Curr Opin Oncol; 2008 Nov; 20(6):639-49. PubMed ID: 18841045
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers.
Aljuffali IA; Fang CL; Chen CH; Fang JY
Curr Pharm Des; 2016; 22(27):4219-31. PubMed ID: 27323758
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.
Tu B; Zhang M; Liu T; Huang Y
Front Cell Dev Biol; 2020; 8():400. PubMed ID: 32582697
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs.
Raza F; Siyu L; Zafar H; Kamal Z; Zheng B; Su J; Qiu M
Curr Pharm Des; 2022; 28(5):380-394. PubMed ID: 34727851
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
15. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
17. Programmable nanomedicine: synergistic and sequential drug delivery systems.
Pacardo DB; Ligler FS; Gu Z
Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
19. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Qiu T; Zhou L; Zhu W; Wang T; Wang J; Shu Y; Liu P
Future Oncol; 2013 Feb; 9(2):255-69. PubMed ID: 23414475
[TBL] [Abstract][Full Text] [Related]
20. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
Urbinati G; Marsaud V; Plassat V; Fattal E; Lesieur S; Renoir JM
Int J Pharm; 2010 Sep; 397(1-2):184-93. PubMed ID: 20603204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
